Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .
Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women.
BACKGROUND Estrogen replacement therapy ( ERT ) , which is mainly used to relieve climacteric symptoms , increases a woman 's risk for uterine endometrial cancer and epithelial ovarian cancer ( EOC ) .  Estrogens are often combined with progestins in hormone replacement therapy ( HRT ) to reduce the risk of uterine endometrial cancer . Data on the association between HRT including progestins and EOC risk are limited . This nationwide case-control study examined EOC risk in relation to HRT regimens with sequentially added progestins ( HRTsp ) and continuously added progestins ( HRTcp ) . METHODS Between 1993 and 1995 , we enrolled 655 histologically verified incident case patients with EOC and 3899 r and omly selected population controls , all 50 - 74 years of age . Data on HRT use were collected through mailed question naires . Multivariate-adjusted odds ratios ( ORs ) and 95 % confidence intervals ( CIs ) were estimated by the use of unconditional logistic regression . RESULTS Risks of EOC were elevated among ever users as compared with never users of both ERT ( OR = 1.43 , 95 % CI = 1.02 to 2.00 ) and HRTsp ( OR = 1.54 , 95 % CI = 1.15 to 2.05 ) ; risks were elevated for serous , mucinous , and endometrioid subtypes . For all EOC types combined , the greatest risk increases were seen with hormone use exceeding 10 years . Ever use of HRTcp was not associated with increased EOC risk relative to HRTcp never use ( OR = 1.02 , 95 % CI = 0.73 to 1.43 ) . The risk of EOC was elevated among HRTsp ever users as compared with HRTcp ever users ( OR = 1.78 , 95 % CI = 1.05 to 3.01 ) . ORs for EOC after ever use of low-potency estrogens were 1.18 ( 95 % CI = 0.89 to 1.55 ) for oral and 1.33 ( 95 % CI = 1.03 to 1.72 ) for vaginal applications , but no relationship was seen between EOC risk and duration of use . CONCLUSION Ever users of ERT and HRTsp but not HRTcp may be at increased risk of EOC
Women taking HT had a significantly decreased incidence of fracture with long-term use .
Research ers found no strong evidence that HT has a clinical ly meaningful impact on the incidence of colorectal cancer .
AUTHORS ' CONCLUSIONS : Women with intolerable menopausal symptoms may wish to weigh the benefits of symptom relief against the small absolute risk of harm arising from short-term use of low-dose HT , provided they do not have specific contraindications .
HT may be unsuitable for some women , including those at increased risk of cardiovascular disease , increased risk of thromboembolic disease ( such as those with obesity or a history of venous thrombosis ) or increased risk of some types of cancer ( such as breast cancer , in women with a uterus ) .
The risk of endometrial cancer among women with a uterus taking oestrogen-only HT is well documented .
HT is not indicated for primary or secondary prevention of cardiovascular disease or dementia , nor for prevention of deterioration of cognitive function in postmenopausal women .
Although HT is considered effective for the prevention of postmenopausal osteoporosis , it is generally recommended as an option only for women at significant risk for whom non-oestrogen therapies are unsuitable .
BACKGROUND : Hormone therapy ( HT ) is widely provided for control of menopausal symptoms and has been used for the management and prevention of cardiovascular disease , osteoporosis and  dementia in older women .
This is an up date d version of a Cochrane review first published in 2005 .
OBJECTIVES : To assess effects of long-term HT ( at least 1 year 's duration ) on mortality , cardiovascular outcomes , cancer , gallbladder disease , fracture and cognition in perimenopausal and postmenopausal women during and after cessation of treatment .